Noscapine, a Non-addictive Opioid and Microtubule-Inhibitor in Potential Treatment of Glioblastoma
- 10 July 2019
- journal article
- review article
- Published by Springer Nature in Neurochemical Research
- Vol. 44 (8) , 1796-1806
Abstract
Noscapine is a phthalide isoquinoline alkaloid that easily traverses the blood brain barrier and has been used for years as an antitussive agent with high safety. Despite binding opioid receptors, noscapine lacks significant hypnotic and euphoric effects rendering it safe in terms of addictive potential. In 1954, Hans Lettré first described noscapine as a mitotic poison. The drug was later tested for cancer treatment in the early 1960's, yet no effect was observed likely as a result of its short biological half-life and limited water solubility. Since 1998, it has regained interest thanks to studies from Emory University, which showed its anticancer activity in animal models with negligible toxicity. In contrast to other microtubule-inhibitors, noscapine does not affect the total intracellular tubulin polymer mass. Instead, it forces the microtubules to spend an increased amount of time in a paused state leading to arrest in mitosis and subsequently inducing mitotic slippage/mitotic catastrophe/apoptosis. In experimental models, noscapine does not induce peripheral neuropathy, which is common with other microtubule inhibitors. Noscapine also inhibits tumor growth and enhances cancer chemosensitivity via selective blockage of NF-κB, an important transcription factor in glioblastoma pathogenesis. Due to their anticancer activities and high penetration through the blood–brain barrier, noscapine analogues strongly deserve further study in various animal models of glioblastoma as potential candidates for future patient therapy.Keywords
This publication has 51 references indexed in Scilit:
- The microtubule binding drug EM011 inhibits the growth of paediatric low grade gliomasCancer Letters, 2013
- Antitumor Activity of Noscapine in Combination with Doxorubicin in Triple Negative Breast CancerPLOS ONE, 2011
- A novel microtubule-modulating agent induces mitochondrially driven caspase-dependent apoptosis via mitotic checkpoint activation in human prostate cancer cellsEuropean Journal of Cancer, 2010
- Noscapine, a Benzylisoquinoline Alkaloid, Sensitizes Leukemic Cells to Chemotherapeutic Agents and Cytokines by Modulating the NF-κB Signaling PathwayCancer Research, 2010
- Antiangiogenic Effects of Noscapine Enhance Radioresponse for GL261 TumorsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Noscapine induces apoptosis in human glioma cells by an apoptosis-inducing factor-dependent pathwayAnti-Cancer Drugs, 2008
- Effect of noscapine and vincristine combination on demyelination and cell proliferationin vitroLeukemia & Lymphoma, 2008
- Noscapine and diltiazem augment taxol and radiation-induced S-phase arrest and clonogenic death of C6 glioma in vitroSurgical Neurology, 2006
- Noscapine Crosses the Blood-Brain Barrier and Inhibits Glioblastoma GrowthClinical Cancer Research, 2004
- SYNERGISTS AND ANTAGONISTS OF MITOTIC POISONSAnnals of the New York Academy of Sciences, 1954